VulCur Medtech

We are developing a painless treatment for chronic wounds without harming human cells to prevent amputations among diabetic patients and other chronic wound patients, thus minimising the need for antibiotics and preventing painful medical procedures. Chronic wounds are accounting for ~5% of the total US healthcare expenditure and result in an amputation every 30s worldwide.
SDGs
Location København
Website vulcur.com
Founded 2018
Employees 1-10
Industries Healthcare & Life Science
Stage Product or prototype
Business model B2B, B2G
Funding state Seed

Team

Founder, CTO
Otto Ømann
JB
Founder, CEO
Janus Beierholm